Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, May 23, 2024 /PRNewswire/ — USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according to Johns Hopkins Medicine up to 80% of patients, are diagnosed at later, more difficult-to-treat stages. Now, researchers have identified specific circulating microRNAs (miRNAs) in blood samples that can identify individuals at high risk of developing pancreatic cancer within 5 years. The American Cancer Society projects that approximately 66,440 individuals in the USA, split between 34,530 men and 31,910 women, will be diagnosed with pancreatic cancer in 2024, with, sadly, about 51,750 expected to die from the disease. In the background, biotech developers are intensely focused on pioneering new medical treatments and significantly enhancing the health outcomes for patients, including recent updates from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX:ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Merus N.V. (NASDAQ: MRUS), and Lantern Pharma Inc. (NASDAQ: LTRN).